CXCR4 and malignant colon neoplasm: In general, the findings suggest that targeting CXCR4 with Pep R enhances the effectiveness of colon cancer treatment by reducing stem-resistant cancer cell proliferation, reversing EMT-induced markers, and inhibiting cell growth.